Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Gene therapy involves the introduction of new genes into cells, to restore or add gene expression, for the purpose of treating disease. Most commonly a mutated gene is replaced with DNA encoding a ...

As a person who “reads all the therapy books,” she said, “I haven’t really seen it be wrong.” Anxious, depressed or just lonely, people who can’t find or afford a professional ...

As a person who “reads all the therapy books,” she said, “I haven’t really seen it be wrong.” Anxious, depressed or just lonely, people who can’t find or afford a professional ...

Anna Kendrick didn't have a good experience in couples therapy. On Wednesday's episode of Alex Cooper's "Call Her Daddy" podcast, the "Pitch Perfect" star said she was in a 7-year relationship ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe ...

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing Phase 2 trial for NTLA-2002, a CRISPR-based gene editing therapy for an ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to ...